Europe's Cannabis Boom Is Accelerating as Billions Flow into Licensed Markets

About this update from Canopy Growth Corporation

[{"type":"text","content":"Europe’s Cannabis Boom Is Accelerating as Billions Flow into Licensed MarketsGermany and other key markets are fueling rising demand for regulated cannabis products and infrastructure\nNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Europe’s licensed cannabis industry is starting to look like one of the most exciting growth stories in the global cannabis market. What was once a fragmented, slow-moving sector is now gaining serious momentum as more countries open up medical cannabis programs, expand patient access, and create clearer licensing frameworks for producers and distributors. Germany continues to lead the charge after its cannabis reforms, but countries like the UK, Portugal, Italy, France, Switzerland, and the Czech Republic are also becoming major pieces of the puzzle. Investors and operators are paying close attention because Europe is increasingly being viewed as the next major long-term cannabis opportunity outside North America. Active Companies in the cannabis/edibles industries of interest include: Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF), Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), Tilray Brands, Inc. (NASDAQ: TLRY), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Organigram Global Inc. (NASDAQ: OGI). The numbers behind the industry are getting hard to ignore. According to market forecasts, the European medical cannabis market was valued at roughly $3.06 billion in 2025 and is projected to climb to more than $13.1 billion by 2034, representing strong double-digit annual growth. Other industry estimates suggest Europe’s legal cannabis sector could reach between €2 billion and €4 billion within the next few years as regulations continue to evolve and patient adoption accelerates. Germany alone now represents one of the largest medical cannabis markets outside of North America, with demand rising sharply as imports, prescriptions, and domestic cultivation expand. What makes Europe especially interesting is that the industry is maturing in a much more structured and pharmaceutical-style environment compared to earlier North American markets. Licensed operators that can meet strict EU-GMP standards are gaining a major competitive advantage, and institutional investors are starting to favor companies with scalable infrastructure, compl...

More updates from Canopy Growth Corporation